m-18

C22:1 1-Deoxyceramide (m18:1/22:1) [C22:1(13Z) 1-Deoxyceramide] is a type of deoxyceramide lipid that lacks the 1-hydroxyl group, making it a variant of ceramide. It has potential neurotoxicity and is involved in mitochondrial stress and cell death signaling. This compound can be utilized in studies of sphingolipid metabolism abnormalities related to neurodegenerative diseases.

1-Deoxyceramide (m18:1/20:0) is a type of ceramide. Its levels increase in the dorsal root ganglia of mice treated with Docetaxel.

Abemaciclib metabolite M18 (LSN3106729) is a potent cyclin-dependent kinase (CDK) inhibitor with antitumor properties. It has been incorporated alongside a cereblon (CRBN) ligand to develop a proteolysis-targeting chimera (PROTAC) that selectively degrades CDK4/6 [1] [2].

Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a, κ antibody inhibitor that targets mouse CD18.

C24:1 1-Deoxyceramide (m18:1(14Z)/24:1) (C24:1 Ceramide (m18:1/24:1)) is an analogue of ceramide.

C6 Dihydro 1-deoxyceramide (m18:0/6:0) (C6 Dihydro ceramide (m18:0/6:0)) is an analogue of ceramide.

C6 1-Deoxyceramide (m18:1/6:0) (C6:0 Ceramide (m18:1/6:0)) is a non-typical short-chain ceramide.

C22 1-Deoxyceramide (m18:1(14Z)/22:0) (also referred to as C22 Ceramide (m18:1/22:0); Cer(m18:1/22:0)) is a long-chain neuroceramide that includes 1-Deoxysphingosine (m18:1(14Z)).

C6 1-Deoxyceramide (m18:1(14Z)/6:0) (Ceramide (m18:1(14Z)/6:0)) is a type of short-chain ceramide that includes 1-Deoxysphingosine (m18:1(14Z)).

OM-189 is a selective inhibitor of synthetic thrombin.

LM-189 is a G protein α subunit I (Gαi)-biased agonist and serves as a Gαi-biased ligand for the β2-adrenergic receptor (β2AR). It stabilizes a specific conformation in TM6 and enhances the dynamics of ICL2. LM-189 is useful for developing Gαi-biased β2AR agonists.

LM-189 free base is a G protein α subunit I (Gαi)-biased agonist and acts as a Gαi-biased ligand for the β2-adrenergic receptor (β2AR). It stabilizes a particular conformation in TM6 and enhances the dynamics of ICL2. LM-189 free base is useful for the development of Gαi-biased β2AR agonists.

PPM-18 (NSC 73233) is a potent anti-inflammatory agent which inhibits nitric oxide synthase expression. PPM-18 is a potent inhibitor of iNOS expression by blocking the binding of NF-κB to promoter [1]. PPM-18 is an analog of Vitamin K remarkably suppressed the proliferation and induced apoptosis in bladder cancer cells [2].

CFM-184 is an orally active factor IXa inhibitor with hFIXa IC50 = 4.9 nM.

SMM-189 is a potent and selective CB2 inverse agonist.

ZM-181037 is an ATP-sensitive potassium channel-blocker and a eukalemic diuretic.

RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in the Ca2+ mobilization assay, and exhibits pIC50s of 5.29 for hCB1 and 6.25 for mCB1.

M 18 is a bioactive chemical.

Fulvestrant (ZM 182780) is an estrogen receptor (ER) antagonist (IC50=9.4 nM) and an agonist of GPR30. Fulvestrant has antitumor activity, inhibiting cell proliferation and inducing apoptosis and autophagy.

Tivicilovir (AM188) is a hepatitis B virus inhibitor. tiviclovir is a guanine-related acyclic 2'-deoxyguanine analogue with anti-herpesvirus activity.

Secnidazole (PM-185184) is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa.

Plinabulin (NPI-2358) (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing tumor cells ( IC50: 9.8-18 nM). Plinabulin selectively targets and binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics. This disrupts mitotic spindle assembly leading to cell cycle arrest at M phase and blockage of cell division.

1-Deoxysphingosine (m18:1(4E)) is an atypical sphingolipid that contains a double bond at the 4E native position and is formed when serine palmitoyltransferase condenses palmitoyl-CoA with alanine instead of serine during sphingolipid synthesis.1,2 Plasma levels of 1-deoxysphingosine (m18:1(4E)) are increased in patients with chronic idiopathic axonal neuropathy (CIAP) and diabetic distal symmetrical polyneuropathy (DSPN).3 |1. Steiner, R., Saied, E.M., Othman, A., et al. Elucidating the chemical structure of native 1-deoxysphingosine. J. Lipid Res. 57(7), 1194-1203 (2016).|2. Alecu, I., Othman, A., Penno, A., et al. Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway. J. Lipid Res. 58(1), 60-71 (2017).|3. Hube, L., Dohrn, M.F., Karsai, G., et al. Metabolic syndrome, neurotoxic 1-deoxysphingolipids and nervous tissue inflammation in chronic idiopathic axonal polyneuropathy (CIAP). PLoS One 12(1):e0170583, (2017).

Dequalinium chloride (Decabis) , a topical bacteriostat, is a selective blocker of apamin-sensitive K+ channels. It is used in wound dressings and mouth infections and may also have antifungal action, but may cause skin ulceration.